If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
95
results.
Updated on
07/06/2025 [07:56:00]
Results 50 to 75 of 95
Absstract of: US2025163388A1
Disclosed herein are methods of deriving, producing, maintaining, or expanding embryonic stem cells (ESCs) from avian species and a culture medium used for such methods. According to various embodiments, the method includes culturing an embryo extracted from an avian egg in a culture medium to harvest cells from yolk of the avian egg; dissociating cells from the cultured embryo; isolating a morphologically undifferentiated ESC colony from the dissociated cells in a culture medium; and culturing the isolated ESC colony in the presence of ovotransferrin, thereby deriving ESCs. According to various embodiments, the culture medium includes a Wnt inhibitor; a protein kinase C (PKC) inhibitor; ovotransferrin; an inhibitor of activin receptor-like kinases-4, -5, and -7; and a leukemia inhibitory factor (LIF).
Absstract of: AU2023361041A1
The invention is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular the invention is directed to a modified-release formulation in form of mini-tablets suitable for twice-a-day oral administration for the treatment of diseases which cause an overload of iron for example, thalassemia, sickle cell anemia, hemochromatosis, and myelodysplasia, or for the prevention and/or treatment of diseases which are caused by an overload of iron. The invention is also directed to methods of making said formulation.
Absstract of: AU2023385479A1
Compositions and methods for treating cancer, particularly leukemia, using a cytotoxic composition comprising monocytes activated by 3-glucan. The monocytes are preferably incubated with the β-glucan and then processed to extract particles, such as microvesicles and exosomes from the treated monocytes to produce the cytotoxic composition. Preferably the cytotoxic composition comprises at least 50% exosomes having a size of 150 nm or less that are activated with β-glucan. Zymosan is the preferred β-glucan. The cytotoxic composition has an apoptosis effect. When a subject having cancer is treated according to preferred embodiments, the cytotoxic composition preferably induces a cytokine response in the subject's immune system. The combination of the cytotoxic composition and cytokine response are synergistic.
Absstract of: AU2023355219A1
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as an active ingredient. The immune cells according to the present invention not only exhibit synergistic tumor cell killing activity through co-expression of the chimeric antigen receptor and IL-15, but also significantly improve survival and in vitro proliferation rates, and can thus be usefully employed as an efficient anti-cancer cell therapy. In particular, when the immune cells of the present invention express a chimeric antigen receptor targeting CD5, the immune cells can be used as an effective treatment composition for various CD5-positive tumors, including lymphocytic leukemia.
Absstract of: AU2023379583A1
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express cytotoxic chimeric receptors and various dosing regimens for administering such cells. In several embodiments, the immune cells express a chimeric receptor that targets ligands of NKG2D on tumor cells. In several embodiments, the cancer is a blood cancer, for example, acute myeloid leukemia (e.g., relapsed/refractory acute myeloid leukemia) or myelodysplastic syndrome. In several embodiments, the tumor is a solid tumor, for example, breast cancer, cervical cancer, colorectal cancer, gastric cancer, head and neck cancers, hepatocellular carcinoma, lung cancer, melanoma, intrahepatic cholangiocarcinoma or other liver tumor, for example, secondary metastases from colorectal cancer. In several embodiments, the immune cells are administered in conjunction with a therapeutic agent, such as an additional anti-cancer agent.
Absstract of: US2025152707A1
The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
Absstract of: US2025154243A1
Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from <5% to >10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from <5% to >10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a second therapeutic agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells, an increased percentage of CD116 and CD131 in CD34+ stem and progenitor cells in the subject compared to a healthy subject and/or an increased percentage of CD14+ cells in the subject compared to a healthy subject. A therapeutically effective amount of a hypomethylating agent or hydroxyurea may b
Absstract of: US2025154144A1
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: WO2025101837A1
Described herein are biological devices and extracts useful for detection of different types of cancer. The biological devices include microbial cells transformed with a DNA construct containing genes for producing peroxidase, terminal deoxynucleotidyl transferase (TdT), CA 125, prostatic acid phosphatase, and CA 15-3. Methods for using the devices to detect various cancers, including leukemia, breast cancer, ovarian cancer, and prostate cancer, are also provided herein. In one aspect, the detection methods can make use of commercial ATP detection kits, electromagnetic measurements, or yellow photonic fluorescence measurements.
Absstract of: US2025154268A1
Disclosed in the present invention is an antibody targeting CD25 or a variant thereof. A monoclonal antibody targeting CD25 is a naturally occurring antibody, has an activity of binding to human CD25 and cynomolgus monkey CD25, and has a stronger ADCC effect after being modified with Fc. In-vitro experiments show that the antibody has the effect of clearing Treg and lymphoma cells without blocking an IL-2 signaling pathway.
Absstract of: WO2025099451A1
The present invention relates to compounds of Formula (I), and sub-formulae thereof, that may act as inhibitors of YTHDC1. The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment of disease and conditions susceptible to YTHDC1 inhibition, such as cancer and in particular acute myeloid leukaemia.
Absstract of: WO2025098432A1
Disclosed is an mIDH1/NAMPT dual-target inhibitor, which is selected from a compound having a structure as shown in formula (I) or formula (II), or a pharmaceutically acceptable salt, racemate, stereoisomer, prodrug, or solvent compound thereof. The dual-target inhibitor of the present invention can effectively overcome the shortcomings of a single mIDH1 inhibitor and single NAMPT inhibitor having poor efficacy against solid tumors. Said inhibitor can inhibit the malignant proliferation of tumors, has a good therapeutic effect, has low toxicity, and can penetrate the blood-brain barrier, and it is not easy to acquire drug resistance to said inhibitor. Moreover, the inhibitor can be used to prepare a medicament for treating cancer or tumor-related diseases, the cancer or tumor-related diseases comprising multiple myeloma, leukemia, breast cancer, prostate cancer, lung cancer, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, and endometrial cancer.
Absstract of: US2025154263A1
Methods are disclosed for treating chronic lymphocytic leukemia (CLL), and other diseases, comprising administrating to a patient an anti-CLECL1 antibody or antigen-binding fragment thereof, as soluble molecules or as components of CAR-T cells or as bi- or tetra-specific antibodies that co-ligate T cells or NK cells and abnormal cells in CLL or other diseases or as bi- or tetra-specific antibodies that bind only the B cells in CLL or only abnormal cells in other diseases. Methods are disclosed for determining residual disease after therapy or predicting disease relapse in a patient comprising analyzing a blood or bone sample from a patient treated for the disease for the presence of CLECL1+ PF cells using a monoclonal antibody to CLECL1 or antigen-binding fragment thereof, wherein reappearance of CLECL1+ PF cells in the blood of the patient is indicative of development of resistance to therapy. Monoclonal antibodies to CLECL1 are disclosed.
Absstract of: WO2025099437A1
A method of predicting the risk of progression of a cancer of a subject is described. The method can be used to infer the historical growth dynamics of an individual's cancer using fluctuating methylation clocks (FMCs). In the case of, for example, chronic lymphocytic leukaemia (CLL) (at least), the inferred growth rate holds valuable prognostic information, enabling patient stratification beyond that of standard clinical practice.
Absstract of: US2025154599A1
The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease, prognostic evaluation and therapy of acute myeloid leukaemia (AML).
Absstract of: WO2025097336A1
The present invention provides an anti-CD30 antigen VHH nanobody. The antibody has the advantages of small relative molecular mass, high affinity, high specificity and stability, good solubility, low immunogenicity and the like. The present invention also constructs a CD30 chimeric antigen receptor and CAR-T cells expressing the chimeric antigen receptor. The use of the CAR-T cells of the present invention for cellular immunotherapy can have a certain treatment effect on various lymphomas.
Absstract of: WO2024008659A1
Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase® has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.
Absstract of: TW202417498A
The present disclosure relates to anti-SCUBE1 antibodies, antigen-binding fragments thereof, and antibody drug conjugates (ADCs), as well as methods of treating and/or preventing SCUBE1-expressing cancers.
Absstract of: NL2039921A
The invention discloses a method for preparing a product to inhibitBrucella based on Brucella OMP25 monoclonal antibody, comprising the following steps: Step 1, antigen preparation and purification; Step 2, animal immunization and spleen cell extraction; Step 3, cell fusion and hybridization optimization; Step 4, antibody preparation and purification; Step 5, product development and application; Step 6, product validation and optimization. The invention achieves high-level recombinant expression of OMP25 protein and ensures high antigen purity, thereby reducing the impact of impurities on subsequent immunization and antibody preparation. By introducing adjuvants, the immune response of mice to the OMP25 antigen is enhanced, increasing the titer and specificity of the antibody and ensuring that the quantity and activity of spleen cells meet the requirements for subsequent cell fusion. Fusion technology improves the fusion efficiency of spleen cells with myeloma cells, while screening technology significantly enhanceshybridoma screening efficiency and clonalization success.
Absstract of: US2025144023A1
The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).
Absstract of: US2025146076A1
Provided herein are anaplastic lymphoma kinase (ALK) fusion nucleic acid molecules and polypeptides, methods related to detecting ALK fusion nucleic acid molecules and polypeptides in cancer, as well as methods of treatment and uses related thereto. Detection of an ALK fusion nucleic acid molecule or polypeptide can be used to identify individuals that may benefit from treatment with an anti-cancer therapy.
Absstract of: WO2025096976A1
Present disclosure relates to compositions and methods for diagnosing subjects afflicted with follicular lymphoma (FL) that are at risk for transforming into diffuse large B- cell lymphoma (DLBCL), methods of predicting responses of subjects with FL or DLBCL to the pharmacological inhibition of SMARCA4/2, as well as methods of preventing and/or treating FL and/or DLBCL, based on the genotype, level, and/or activity of ARID 1 A.
Absstract of: WO2025096844A2
The present disclosure provides methods of treating lymphoma comprising administering a bispecific CD20xCD3 antibody to a patient in need thereof, wherein the patient is selected on the basis of exhibiting a modified level of circulating tumor (ct) DNA. In certain embodiments, the present disclosure provides methods of identifying a patient with lymphoma who is likely to respond favorably to therapy comprising a bispecific CD20xCD3 antibody.
Absstract of: WO2025094107A1
Embodiments relate to methods of treating high-risk smoldering multiple myeloma in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a BCMAxCD3 bispecific antibody.
Nº publicación: WO2025096700A1 08/05/2025
Applicant:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Absstract of: WO2025096700A1
The present disclosure provides a method of treating chronic myelomonocytic leukemia in a subject in need of such treatment, comprising administrating to the subject a janus kinase (JAK) inhibitor and a hypomethylating agent. In an example the JAK inhibitor is pacritinib and the hypomethylating agent is azacitidine.
BOPI
Electronic site
